Daniel Gold, president and CEO of MEI Pharma, expressed the company’s satisfaction with the FDA’s designation.

Acute myeloid leukemia “is a particularly devastating cancer for which there are currently few broadly effective treatments,” Gold said. “Through development of Pracinostat, we hope to address this significant unmet medical need.”